Substituted cathinone

Monoamine release profiles

The following is a list of serotonin, dopamine, and norepinephrine releasing profiles for various cathinones, measured in rat brain synaptosomes.

List of substituted cathinones

The derivatives may be produced by substitutions at four locations of the cathinone molecule:

• R1 = hydrogen, or any combination of one or more alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents
• R2 = hydrogen or any alkyl group
• R3 = hydrogen, any alkyl group, or incorporation in a cyclic structure
• R4 = hydrogen, any alkyl group, or incorporation in a cyclic structure

The following table displays notable derivatives that have been reported:

Legality

On 2 April 2010, the Advisory Council on the Misuse of Drugs in the UK announced that a broad structure-based ban of this entire class of compounds would be instituted, following extensive publicity around grey-market sales and recreational use of mephedrone, a common member of the family. This ban covers compounds with the aforementioned general structure, with 28 compounds specifically named.

(i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;

(ii) by substitution at the 3-position with an alkyl substituent;

(iii) by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure."|ACMD, 2 April 2010}}

This text was added as an amendment to the Misuse of Drugs Act 1971, to come into force on 16 April 2010. Note that four of the above compounds (cathinone, methcathinone, diethylpropion and pyrovalerone) were already illegal in the UK at the time the ACMD report was issued. Two compounds were specifically excluded from the ban, these being bupropion because of its common use in medicine and relative lack of abuse potential, and naphyrone because its structure falls outside the generic definition and not enough evidence was yet available to justify a ban.

Naphyrone analogues were subsequently banned in July 2010 following a further review by the ACMD, along with a further broad based structure ban even more expansive than the last.

further modified in any of the following ways, that is to say—

(i) by substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;

(ii) by substitution at the 3–position with an alkyl substituent;

(iii) by substitution at the 2-amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure".|Home Office, 13 July 2010.}}

• Cyc = any monocyclic, or fused-polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), including analogues where the ring system is substituted to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents
• R1 = hydrogen or any alkyl group
• R2 = hydrogen, any alkyl group, or incorporation in a cyclic structure
• R3 = hydrogen, any alkyl group, or incorporation in a cyclic structure

More new derivatives have however continued to appear, with the UK reporting more novel cathinone derivatives detected in 2010 than any other country in Europe, with most of them first identified after the generic ban had gone into effect and thus already being illegal despite never having been previously reported.

In the United States, substituted cathinones are the psychoactive ingredients in "bath salts" which as of July 2011 were banned by at least 28 states, but not by the federal government.

References

References

1. (February 2006). "1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors". Journal of Medicinal Chemistry.
2. (2014). "Emerging drugs of abuse: current perspectives on substituted cathinones". Substance Abuse and Rehabilitation.
3. (October 2018). "DARK Classics in Chemical Neuroscience: Cathinone-Derived Psychostimulants". ACS Chemical Neuroscience.
4. (April 2018). "Intoxications in the STRIDA project involving a panorama of psychostimulant pyrovalerone derivatives, MDPV copycats". Clinical Toxicology.
5. (2018). "The newest cathinone derivatives as designer drugs: an analytical and toxicological review". Forensic Toxicology.
6. (2011). "Khat use is associated with impaired working memory and cognitive flexibility". PLOS ONE.
7. (2003). "Monoamine transporters and psychostimulant drugs". Eur. J. Pharmacol..
8. (2006). "Therapeutic potential of monoamine transporter substrates". Curr Top Med Chem.
9. (February 2015). "Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter". Drug and Alcohol Dependence.
10. (December 2005). "Targeted screening for biogenic amine transporters: potential applications for natural products". Life Sciences.
11. (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse.
12. (April 2012). "The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue". Neuropsychopharmacology.
13. (May 2023). "A narrative review of the neuropharmacology of synthetic cathinones-Popular alternatives to classical drugs of abuse". Hum Psychopharmacol.
14. (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". J Pharmacol Exp Ther.
15. (April 2014). "Monoamine transporter and receptor interaction profiles of a new series of designer cathinones". Neuropharmacology.
16. (October 2020). "In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor". Arch Toxicol.
17. (2011). "Trifluoromethyl ring-substituted methcathinone analogs: activity at monoamine uptake transporters". The FASEB Journal.
18. (June 2014). "Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics". ACS Med Chem Lett.
19. (9 March 2023). "Norfenfluramine to treat dravet syndrome".
20. (2014). "Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse". Academic Press.
21. (October 2013). "Effects of methcathinone and 3-Cl-methcathinone (PAL-434) in cocaine discrimination or self-administration in rhesus monkeys". Int J Neuropsychopharmacol.
22. (March 2019). "The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes". Psychopharmacology.
23. "Specialized combinations for mental disorders or mental enhancement".
24. Sakloth, Farhana. (11 December 2015). "Psychoactive synthetic cathinones (or 'bath salts'): Investigation of mechanisms of action".
25. (March 2024). "Structure-activity relationships for locomotor stimulant effects and monoamine transporter interactions of substituted amphetamines and cathinones". Neuropharmacology.
26. Nicole, Lauren. (2022). "In vivo Structure-Activity Relationships of Substituted Amphetamines and Substituted Cathinones".
27. (May 2015). "Quantitative structure-activity relationship analysis of the pharmacology of para-substituted methcathinone analogues". Br J Pharmacol.
28. (2017). "Neuropharmacology of New Psychoactive Substances (NPS)".
29. (April 2017). "The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse". J Med Chem.
30. (2018). "Neuropharmacology of Synthetic Cathinones". Handb Exp Pharmacol.
31. (January 2013). "Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs". Eur J Pharmacol.
32. (June 2020). "Investigation of the Optical Isomers of Methcathinone, and Two Achiral Analogs, at Monoamine Transporters and in Intracranial Self-Stimulation Studies in Rats". ACS Chem Neurosci.
33. Nguyen, Vy. (2019). "Analyzing Interactions Between Methcathinone Analogs and the Human Monoamine Transporters". VCU Theses and Dissertations.
34. Yadav, Barkha J. (16 July 2019). "Understanding Structure–Activity Relationship of Synthetic Cathinones (Bath Salts) Utilizing Methylphenidate".
35. (December 2000). "Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters". Bioorganic & Medicinal Chemistry.
36. (1999). "Problems of Drug Dependence 1999: Proceedings of the 61st Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc".
37. Davies, Rachel A. (10 July 2019). "Structure-Activity Relationship Studies of Synthetic Cathinones and Related Agents".
38. (June 2017). "Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release". ACS Chem Neurosci.
39. (March 2019). "The synthetic cathinones, butylone and pentylone, are stimulants that act as dopamine transporter blockers but 5-HT transporter substrates". Psychopharmacology (Berl).
40. (June 2013). "Substituted methcathinones differ in transporter and receptor interactions". Biochem Pharmacol.
41. (July 2008). "Dopamine Transporters: Chemistry, Biology and Pharmacology". Wiley.
42. (June 2013). "Amphetamine, past and present--a pharmacological and clinical perspective". Journal of Psychopharmacology.
43. (February 2016). "Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats". Eur Neuropsychopharmacol.
44. (October 2003). "Monoamine transporters and psychostimulant drugs". European Journal of Pharmacology.
45. (September 2015). "Ethylenedioxy homologs of N-methyl-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) and its corresponding cathinone analog methylenedioxymethcathinone: Interactions with transporters for serotonin, dopamine, and norepinephrine". Bioorg Med Chem.
46. (March 2019). "Analytical quantification, intoxication case series, and pharmacological mechanism of action for N-ethylnorpentylone (N-ethylpentylone or ephylone)". Drug Test Anal.
47. (April 2021). "Eutylone and Its Structural Isomers Interact with Monoamine Transporters and Induce Locomotor Stimulation". ACS Chem Neurosci.
48. (March 2013). "Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products". Neuropsychopharmacology.
49. (February 2015). "Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats". Br J Pharmacol.
50. Shalabi, Abdelrahman R.. (14 December 2017). "Structure-Activity Relationship Studies of Bupropion and Related 3-Substituted Methcathinone Analogues at Monoamine Transporters".
51. (January 2019). "Systematic Structure-Activity Studies on Selected 2-, 3-, and 4-Monosubstituted Synthetic Methcathinone Analogs as Monoamine Transporter Releasing Agents". ACS Chem Neurosci.
52. (February 2017). "Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats". Neuropsychopharmacology.
53. (March 2017). "Synthesis, characterization and monoamine transporter activity of the new psychoactive substance mexedrone and its N-methoxy positional isomer, N-methoxymephedrone". Drug Test Anal.
54. (September 2016). "Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters". Br J Pharmacol.
55. [http://www.emcdda.europa.eu/system/files/publications/550/2008_Implementation_report_281411.pdf Europol 2008 Annual Report on the implementation of Council Decision 2005/387/JHA]
56. [http://www.emcdda.europa.eu/system/files/publications/553/2009_Implementation_report_281420.pdf Europol 2009 Annual Report on the implementation of Council Decision 2005/387/JHA]
57. [http://www.emcdda.europa.eu/system/files/publications/644/EMCDDA-Europol_Annual_Report_2010A_281336.pdf Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA]
58. [http://www.emcdda.europa.eu/system/files/publications/689/EMCDDA-Europol_Annual_Report_2011_2012_final_335568.pdf Europol 2011 Annual Report on the implementation of Council Decision 2005/387/JHA]
59. [http://www.emcdda.europa.eu/system/files/publications/734/EMCDDA-Europol_2012_Annual_Report_final_439477.pdf Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA]
60. [http://www.emcdda.europa.eu/system/files/publications/814/TDAN14001ENN_475519.pdf Europol 2013 Annual Report on the implementation of Council Decision 2005/387/JHA]
61. [http://www.emcdda.europa.eu/system/files/publications/1018/TDAN15001ENN.pdf Europol 2014 Annual Report on the implementation of Council Decision 2005/387/JHA]
62. [http://www.emcdda.europa.eu/system/files/publications/2880/TDAS16001ENN.pdf Europol 2015 Annual Report on the implementation of Council Decision 2005/387/JHA]
63. [http://www.emcdda.europa.eu/system/files/publications/4724/TDAN17001ENN_PDFWEB.pdf Europol 2016 Annual Report on the implementation of Council Decision 2005/387/JHA]
64. [http://www.emcdda.europa.eu/system/files/publications/9282/20183924_TDAN18001ENN_PDF.pdf Europol 2017 Annual Report on the implementation of Council Decision 2005/387/JHA]
65. European Monitoring Center for Drugs and Drug Addiction. (December 2020). "New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. An update from the EU Early Warning System". Publications Office of the European Union.
66. (April 2004). "Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis". Therapeutic Drug Monitoring.
67. (April 2012). "The characterisation of two halogenated cathinone analogues: 3,5-difluoromethcathinone and 3,5-dichloromethcathinone". Forensic Science International.
68. (August 2017). "Identification and analytical characterization of nine synthetic cathinone derivatives N-ethylhexedrone, 4-Cl-pentedrone, 4-Cl-α-EAPP, propylone, N-ethylnorpentylone, 6-MeO-bk-MDMA, α-PiHP, 4-Cl-α-PHP, and 4-F-α-PHP". Drug Testing and Analysis.
69. (2019). "Identification and structural characterization of synthetic cathinones: N-propylcathinone, 2,4-dimethylmethcathinone, 2,4-dimethylethcathinone, 2,4-dimethyl-α-pyrrolidinopropiophenone, 4-bromo-α-pyrrolidinopropiophenone, 1-(2,3-dihydro-1H-inden-5-yl)-2-(pyrrolidin-1-yl)hexan-1-one and 2,4-dimethylisocathinone.". Forensic Toxicol.
70. (January 2016). "Analytische Daten neuer 2-aminosubstituierter Methylendioxyvalerophenonderivate.". Toxichem Krimtech.
71. (2018). "The newest cathinone derivatives as designer drugs: an analytical and toxicological review". Forensic Toxicology.
72. (February 2018). "Prediction of designer drugs: Synthesis and spectroscopic analysis of synthetic cathinone analogs that may appear on the Swedish drug market". Drug Testing and Analysis.
73. (May 2019). "Forensic drug analysis of chloro-N,N-dimethylcathinone (CDC) and chloroethcathinone (CEC): Identification of 4-CDC and 4-CEC in drug seizures and differentiation from their ring-substituted positional isomers". Forensic Science International.
74. (November 2020). "New psychoactive versus conventional stimulants - a ten-year review of casework in Hungary". Legal Medicine.
75. (2020). "Interpol review of controlled substances 2016-2019". Forensic Science International. Synergy.
76. "Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista". Finlex Data Bank.
77. link. (22 September 2011 Retrieved 2011-07-17.)
78. "The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2010 No. 1144". Opsi.gov.uk.
79. (2010-07-12). "NRG-1 'legal high' drug is banned". BBC News.
80. (2010-07-07). "Advisory Council on the Misuse of Drugs Naphyrone Report (2010)". Home Office.
81. "Explanatory Memorandum To The Misuse of Drugs (Amendment No. 2) (England, Wales and Scotland) Regulations 2010 No. 1799". Opsi.gov.uk.
82. "The Misuse of Drugs (Amendment No. 2) (England, Wales and Scotland) Regulations 2010 No. 1799". Opsi.gov.uk.
83. European Monitoring Centre on Drugs and Drug Addiction. [http://www.emcdda.europa.eu/attachements.cfm/att_132857_EN_EMCDDA-Europol%20Annual%20Report%202010A.pdf EMCDDA–Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA.] {{Webarchive. link. (14 March 2012 Retrieved 2011-07-17.)
84. (16 July 2011). "An Alarming New Stimulant, Legal in Many States.". [[The New York Times]].